EULAR recommendations for the management of systemic lupus erythematosus: 2023 update


Handling editor David S Pisetsky

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/ard-2023-224762).

For numbered affiliations see end of article.

Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, “Attikon” University Hospital, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens 12462, Greece; boumpas@ioc.gr

Received 22 July 2023
Accepted 18 September 2023

ABSTRACT

Objectives To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence.

Methods An international Task Force formed the questions for the systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation of the statements after a series of meetings. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strength of recommendations were assigned, and participants finally provided their level of agreement with each item.

Results The Task Force agreed on 5 overarching principles and 13 recommendations, concerning the use of hydroxychloroquine (HCQ), glucocorticoids (GC), immunosuppressive drugs (ISDs) (including methotrexate, mycophenolate, azathioprine, cyclophosphamide (CYC)), calcineurin inhibitors (CNIs, cyclosporine, tacrolimus, voclosporin) and biologics (belimumab, anifrolumab, rituximab). Advice is also provided on treatment strategies and targets of therapy, assessment of response, combination and sequential therapies, and tapering of therapy. HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual’s risk for flares and retinal toxicity. GC are used as ‘bridging therapy’ during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and, when possible, withdrawn. Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered. Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative measures for infections, osteoporosis, cardiovascular disease.

Conclusion The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.

INTRODUCTION

Since 2008, when the first EULAR recommendations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring, neuropsychiatric SLE and women’s health issues in SLE have been developed.2–5 More recently, updated recommendations on the management of general SLE and LN were published in 2019 and 2020, respectively, the latter jointly with the European Renal Association/European Dialysis and Transplant Association (ERA/EDTA).

Since the 2019 update, the pace of new developments in SLE has accelerated. A second biological drug, anifrolumab, has been approved for the management of the disease, while the field of LN has also witnessed major breakthroughs; the approval of belimumab and voclosporin, a novel calcineurin inhibitor (CNI), for patients with active LN has inspired discussions on a ‘paradigm shift’ in the treatment of LN, moving from the traditional ‘induction-maintenance’ regimen to the early use of combination therapies.6,7 These advances created the impetus for an update of the recommendations, to provide guidance on an evolving landscape and capitalise on the experience gained thus far.
the drug pipeline and lessons learnt regarding trial design from previous trial failures, it is likely that new therapeutic options will continue to emerge, and SLE may finally enter the era of more frequent updates of its management recommendations, similar to other diseases.8 9

METHODS

Per the EULAR standard operating procedures (SOPs)10 and the AGREE II document,11 the convenor (DTB) submitted a proposal for an update of the recommendations for the management of SLE, which was approved by the EULAR Quality of Care Subcommittee and the EULAR Council. Following approval, a Task Force was assembled to form the research questions for the systematic literature review (SLR), that consisted of 35 rheumatologists, five nephrologists and two patient representatives (JA, MKou), also including two methodologists (GB, CBM) and two fellows responsible for the SLR (AF, MK). Importantly, the Task Force also included non-European experts, four from the Americas (two from the USA (RF, MP), one from Canada (DDG), one from Argentina (BAPE)), four from Asia (SCB, CCM, SVN, YT) and one from Australia (EM). EMerging EUlar NET work was also represented by two members (JM, CW). All members completed a COI form.

Before the first meeting, an outline of the proposed methodology, a set of the main research questions and the respective Population, Intervention, Comparison and Outcomes (PICO) queries were circulated among the panellists, who were encouraged to comment, edit and propose additional topics for the SLR. Through this process, it was decided that the SLRs would focus on five domains: (1) management of general and organ-specific SLE, (2) targets of treatment, (3) tapering/withdrawal of treatment, (4) management of patients with SLE and anti-phospholipid syndrome (APS), and (5) the efficacy and safety of vaccination against herpes zoster and SARS-CoV2 viruses (a general SLR for infection prevention was not decided, as there are dedicated EULAR recommendations on this topic). Separate PICO and search strings were developed for each domain, resulting in five SLRs. The two fellows, supervised by the methodologists, performed the PICO-based SLRs using two different databases (PubMed and Central). Importantly, since the previous recommendations on general SLE had included papers through December 2017, the current SLRs were limited to English language publications published between January 2018 and December 2022. Pertinent articles identified by manual search within the reference list of the originally retrieved publications were also included. A risk of bias assessment was performed using the Cochrane Risk of Bias tool and Newcastle-Ottawa scale for randomised controlled trials (RCT) and observational studies, respectively. The final level of evidence and grading of recommendations, according to the Oxford Evidence-based Medicine grading levels,12 considered also the body of evidence that had informed the 2019 EULAR recommendations.13

The results of the SLRs, focusing on new evidence and data quality, were presented during the first meeting (29 April 2023), held virtually to facilitate the attendance of the international Task Force members. The participants reviewed the evidence, and an initial draft of the statements/recommendations was formulated following open deliberations. Then, suggestions and edits by all members were incorporated by the convenor, methodologists and the fellows responsible for the SLR to a new modified set of recommendations, which was again circulated to the panel members to propose any additional changes. To achieve consensus, a second meeting was held (7 May 2023), in which panelists discussed in detail each overarching principle and recommendation and came up with the final version which served as basis for the voting. During the third and last meeting (14 May 2023), all Task Force members who were present, were asked to vote per bullet point whether they agreed or not in principle with the respective statement. As per the EULAR SOPs, a recommendation was immediately accepted if more than 75% of those present voted in favour. In cases where consensus was not met, possible causes of disagreement were discussed, amendments to the statements were made and a second round of voting requiring more than 66% agreement from participants took place. Following approval of the recommendation, every Task Force member provided their level of agreement (LoA) for each statement in a scale from 0 (no agreement at all) to 10 (100% agreement).

Of note, the 2019 recommendations counted a total of 33 recommendations belonging to 4 domains (goals of treatment, general principles of treatment, specific manifestations and comorbidities). The current update aligns with the EULAR SOPs to include a maximum 15 bullet point statements. To this end, recommendations from the previous set were either omitted or merged, and new recommendations were formulated. Because of this change from the previous update, all overarching principles and individual recommendations are hereby presented as new, even for individual recommendations where the essence has remained unchanged, because a detailed description of ‘merged’, ‘omitted’ and ‘rephrased’ statements was considered impractical.

RESULTS

Following the meetings mentioned above, the Task Force formulated a final number of 5 overarching principles and 13 recommendations (table 1). The detailed results of the SLR are summarised in the online supplemental appendix; however, parts of the data are also presented herein, to provide an explanation of the results.

Overarching principles

The overarching principles contain general information on the management of SLE, reflect common sense and are not accompanied by a respective level of evidence. They are nevertheless important to set an overall framework for the approach to a patient with SLE and highlight the role of physician–patient interaction. The overarching principles were voted as a group of principles (ie, not individually) and agreement was 100%.

A. SLE requires multidisciplinary, individualised management with patient education and shared decision-making, taking into consideration the costs to patient and society.

While rheumatologists are the specialists who should primarily care for patients with SLE, the multisystem nature of the disease often mandates the involvement of other disciplines (eg, nephrologists, dermatologists etc), and treatment decisions should be individualised considering patient preferences and patient education. Comparative costs of different treatments should be weighed against the cost of illness and the societal impact of SLE, in terms of social and work participation. Mean (SD) LoA was 9.88 (0.40).

B. SLE disease activity should be assessed at each clinic visit (the frequency depending on physician’s discretion), with evaluation of organ damage (at least annually), using validated instruments.

Task Force members agreed on the need to formally assess lupus disease activity at each visit for the need of therapy adaptation. The phrasing ‘frequency depending on physician’s discretion’ was decided following deliberations, in which it became
clear that optimal frequency of patient visits may vary, from a few days in a patient with active LN to up to 6 months in patients with long-standing quiescent disease; thus, judgement of the treating physician cannot be substituted by a fixed range of intervals. The most frequently used validated instruments for measuring disease activity are the various versions of the SLE Disease Activity Index (SELENA-SLEDAI or SLEDAI-2K) and the British Isles Lupus Assessment Group (BILAG). Annual assessment of irreversible damage is important because damage accrual has significant prognostic value. Mean (SD) LoA for this principle was 9.74 (0.63).

C. Non-pharmacological interventions, including sun protection, smoking cessation, healthy, balanced diet, regular exercise and measures to promote bone health are important to improve long-term outcomes.

These interventions are not specific to SLE and pertain also to the general population, although patients with lupus should particularly avoid sun exposure due to the characteristic photosensitivity of the disease. The importance of smoking cessation should be emphasised, as smoking may also interfere with the efficacy of antimalarials and biologics (belimumab) among its other detrimental sequelae. Importantly, a dedicated set of EULAR recommendations on non-pharmacological management of SLE and systemic sclerosis were published recently; the reader is referred there for more relevant information. Mean (SD) LoA was 9.90 (0.37).

D. Pharmacological interventions are directed by patient characteristics, type and severity of organ involvement, treatment-related harms, comorbidities, risk for progressive organ damage, and patient preferences.

The phenotypic heterogeneity and variable severity of organ involvement, as well as differential response to drugs based on patient characteristics, mandate an individualised approach. Pharmacological treatment of lupus may range from hydroxychloroquine (HCQ) monotherapy for patients with mild skin and/or joint symptoms, to highly potent immunosuppressive medications like high-dose glucocorticoids (GC) and cyclophosphamide (CYC) in patients with organ-threatening or life-threatening disease. When choosing therapy, immutable characteristics, such as race and ethnicity, as well as socioeconomic determinants and access to different drugs should be taken into account. For example, black patients with LN may be more responsive to mycophenolate than CYC. Patient research partners in the Task Force highlighted the importance of patient preferences in the treatment decisions, which form the basis of shared decision-making. This principle received the highest mean LoA, mean (SD) 10 (0), indicating complete agreement of all individual panellists.

Table 1 EULAR Recommendations for the management of patients with systemic lupus erythematosus—2023 update

<table>
<thead>
<tr>
<th>Recommendation/statement</th>
<th>Level of agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Hydroxychloroquine is recommended for all patients (1bA), unless contraindicated, at a target dose of 5 mg/kg real body weight/day (2bB) but individualised based on risk for flare (2bB) and retinal toxicity.</td>
<td>9.21 (1.35) 90.4</td>
</tr>
<tr>
<td>2. Glucocorticoids, if needed, are dosed based on the type and severity of organ involvement (2bB/C) and should be reduced to maintenance dose of &lt;5 mg/day (prednisone equivalent) (2aB) and, when possible, withdrawn in patients with moderate-to-severe disease, pulses of intravenous methylprednisolone (125–1000 mg/day, for 1–3 days) (3bB/C) can be considered.</td>
<td>9.57 (0.77) 96.6</td>
</tr>
<tr>
<td>3. In patients not responding to hydroxychloroquine (alone or in combination with glucocorticoids) or patients unable to reduce glucocorticoids below doses acceptable for chronic use, addition of immunomodulating/immunosuppressive agents (eg, methotrexate (1bB), azathioprine (2bC) or mycophenolate (2bA)) and/or biological agents (eg, belimumab (1aA) or rituximab (1aA)) should be considered.</td>
<td>9.32 (0.91) 95.2</td>
</tr>
<tr>
<td>4. In patients with organ-threatening or life-threatening disease, intravenous cyclophosphamide (2bC) should be considered; in refractory cases, rituximab (2bB) may be considered.</td>
<td>9.38 (0.99) 95.2</td>
</tr>
<tr>
<td>5. Treatment of active skin disease should include topical agents (glucocorticoids, calcineurin inhibitors (2bB), antimalarials (hydroxychloroquine, chloroquine) (1aA), and/or systemic glucocorticoids (4/C) as needed, with methotrexate (1bB/C), mycophenolate (4/C), azathioprine (1aA), or rituximab (1aB) considered as second-line therapy.</td>
<td>9.35 (1.06) 95.2</td>
</tr>
<tr>
<td>6. In active neuropsychiatric disease attributed to SLE, glucocorticoids and immunosuppressive agents for inflammatory manifestations (1bA) and antplatelet agents/anticoagulants for atherothrombotic/pla related manifestations (2bC) should be considered.</td>
<td>9.68 (0.81) 97.6</td>
</tr>
<tr>
<td>7. For acute treatment of severe autoimmune thrombocytopenia, high-dose glucocorticoids (including pulses of intravenous methylprednisolone) (4/C), with or without intravenous immunoglobulin G (4/C), and/or rituximab (2bB), and/or high-dose intravenous cyclophosphamide (4/C), followed by maintenance therapy with rituximab (2bB), azathioprine (2bC), mycophenolate (2bC), or cyclophosphamide (4/C) should be considered.</td>
<td>9.48 (0.86) 97.6</td>
</tr>
<tr>
<td>8. Patients with active proliferative lupus nephritis should receive low-dose (EuroLupus) intravenous cyclophosphamide (1aA) or mycophenolate (1aA) and glucocorticoids (pulses of intravenous methylprednisolone followed by lower oral doses); combination therapy with belimumab (either with cyclophosphamide or mycophenolate (1bA/B) or calcium inhibitors (especially esotoxin or tazarotem, combined with mycophenolate, 1bA) should be considered.</td>
<td>9.36 (1.06) 92.8</td>
</tr>
<tr>
<td>9. Following renal response, treatment of lupus nephritis should continue for at least 3 years (2bB); patients initially treated with mycophenolate alone or in combination with belimuma or a calcineurin inhibitor should remain on these drugs (1aA), whereas azathioprine or mycophenolate should replace cyclophosphamide for those initially treated with cyclophosphamide alone (1aA) or in combination with belimumab (1aA).</td>
<td>9.56 (0.81) 95.2</td>
</tr>
<tr>
<td>10. In patients at high-risk for renal failure (defined as reduced GFR, histological presence of cellular crescents or fibrinoid necrosis, or severe interstitial inflammation), high-dose (NIH regimen) intravenous cyclophosphamide (1aA) in combination with pulse intravenous methylprednisolone, can be considered.</td>
<td>9.57 (0.86) 95.2</td>
</tr>
<tr>
<td>11. In patients with SLE achieving sustained remission, gradual tapering of treatment should be considered, with withdrawal of glucocorticoids first (2aB).</td>
<td>9.89 (0.38) 90.4</td>
</tr>
<tr>
<td>12. SLE associated with thrombotic antiphospholipid syndrome (APS) should be managed with long-term vitamin K antagonists after the first arterial or unprovoked venous thrombotic event (1bB); low dose aspirin (75–100 mg/day) should be considered in patients with SLE without APS but with high-risk APL profile (2aB).</td>
<td>9.57 (0.83) 97.6</td>
</tr>
<tr>
<td>13. Immunisations for the prevention of infections (herpes zoster virus, human papillomavirus, influenza, COVID-19 and pneumococcus), management of bone health, nephroprotection and cardiovascular risk, and screening for malignancies, should be performed (SD).</td>
<td>9.85 (0.36) 90.4</td>
</tr>
</tbody>
</table>


aPL, antiphospholipid antibodies; GFR, glomerular filtration rate; NIH, National Institutes of Health; SLE, systemic lupus erythematosus.
E. Early SLE diagnosis (including serological assessment), regular screening for organ involvement (especially nephritis), prompt initiation of treatment aiming at remission (or low disease activity if this is not possible), and strict adherence to treatment are essential to prevent flares, and organ damage, improve prognosis and enhance quality of life.

The final overarching principle highlights four pillars in the management of SLE: (1) need for early diagnosis, because despite increased awareness in combination with the new, more sensitive classification criteria, recent studies support that patients with SLE still face diagnostic delay (median 2 years from onset of symptoms); (2) vigilant monitoring for new organ involvement, mainly LN, especially during the first years of the disease, but also thereafter. This need for increased awareness for signs of new-onset kidney involvement was emphasised by several Task Force members, because LN represents a major milestone in the natural history of the disease and delaying its diagnosis has profound prognostic repercussions; (3) pursuing a treatment target, which should ideally be remission, as defined by the recent Definition Of Remission In SLE (DORIS) criteria, or alternatively, a state of low disease activity, such as the Lupus Low Disease Activity state (LLDAS). Both remission and LLDAS have been extensively validated and proven to reduce the risk for damage and other adverse outcomes in patients with SLE (a detailed analysis of the favourable outcomes associated with remission and LLDAS is given in the online supplemental appendix); and (4) the importance of patient adherence to treatment. Specific reference to the issue of adherence in the overarching principles was emphasised by several panellists, including the patient research partners, because medication non-adherence, despite reported wide variations, is considered a major cause of treatment failure. A trusting relationship between the physician and patient forms the basis for the minimisation of the risk of non-adherence. Mean (SD) LoA for the final overarching principle was 9.81 (0.51).

Individual recommendations
1. Hydroxychloroquine is recommended for all patients (1b/A), unless contraindicated, at a target dose of 5 mg/kg real body weight/day (2b/B), but individualised based on risk for flare (2b/B) and retinal toxicity.

HCQ is the mainstay of treatment for patients with SLE and the current SRLR extended the existing body of evidence regarding the multiple beneficial effects of HCQ in various aspects of the disease. In the 2019 recommendations, emphasis was placed on the specification that HCQ dose ‘should not exceed 5 mg/kg real body weight/day’, in view of data which suggested a higher than previously thought risk for retinal toxicity by the use of more sensitive screening techniques. A recent observational study assessed the risk for flares in relation to HCQ dose during the previous 6-month period and found an almost twofold risk for any flare for doses ≤5 mg/kg/day (vs >5 mg/kg/day), increased to more than sixfold for moderate or severe flares, with a threshold dose calculated near 5 mg/kg/day. Until more data become available regarding benefit-risk relationship of different doses, it was decided that the HCQ target dose remains at 5 mg/kg/day; however, this should be individualised based on risk for flare and retinal toxicity, with patients at higher risk for retinal toxicity (kidney disease, preexisting macular or retinal disease, tamoxifen use) being candidates for closer ophthalmologic follow-up. In selected patients and circumstances (eg, moderate or severe disease), initial HCQ dose higher than 5 mg/kg/day (but not exceeding 400 mg/day) may be used, followed by lowering of the dose to within range once the patient has improved. In addition, Task Force members suggested the use of monitoring HCQ blood levels to guide the optimal dose for each patient and assess for possible non-adherence to therapy, based on studies suggesting that HCQ whole blood levels may reflect patient adherence to treatment. Although a universal recommendation for HCQ blood level monitoring would be impractical, it can nevertheless be used to guide dosage adaptations, in settings where it is available. Finally, the use of antimalarials other than HCQ was discussed mainly by non-European panellists, to address the issue of potential limited availability or higher cost of HCQ in some countries. In such settings, chloroquine may be used as an alternative, bearing in mind that it may be more toxic than HCQ (mainly for retinal toxicity). Finally, quinacrine can be considered in patients with cutaneous manifestations and HCQ-induced retinopathy. The statement on HCQ was agreed on by 77.8% of participants following one round of amendments (the only statement where this was needed) and mean (SD) LoA was 9.21 (3.35).

2. Glucocorticoids, if needed, are dosed based on the type and severity of organ involvement (2b/C), and should be reduced to maintenance dose of ≤5 mg/day (prednisone equivalent) (2a/B) and, when possible, withdrawn; in patients with moderate-to-severe disease, pulses of intravenous methylprednisolone (125–1000 mg per day, for 1–3 days) (3b/C) can be considered.

Minimisation of GC use, in view of their detrimental effects, was a major theme of discussion during the Task Force meetings. Numerous studies in the current SRLR confirmed associations of different cut-offs for daily prednisone dose with adverse outcomes, most of which pointed to the threshold of 5 mg/day. Although a controlled trial of different GC tapering regimens or maintenance doses is still lacking in SLE, the Task Force elected to lower the ‘acceptable’ threshold of daily prednisone dose for maintenance treatment to maximum 5 mg/day prednisone equivalent, as compared with 7.5 mg/day in the 2019 recommendations. Ideally, one could envision the use of GC only as ‘bridging therapy’ in SLE, similar to rheumatoid arthritis (lowest possible dose for the shortest possible period), and the complete withdrawal of GC is the optimal target.

Intravenous pulses of methylprednisolone (MP) of various doses (depending on disease severity and patient weight) capitalise on the immediate non-genomic effects of GC, and may allow for a faster tapering of per os (PO) GC. Importantly, pulse IV MP has not been linked to certain established GC-related harms, like avascular necrosis. Initial PO dose also depends on disease severity; a retrospective study in 206 patients with LN using propensity score matching found higher rates of 1-year complete response in patients who started with ≥40 mg/day compared with those who started with ≤30 mg/day, without increased risk for GC-related damage. A smaller study in non-renal lupus had found similar reduction in disease activity at 1 year and higher risk of damage with starting dose >30 mg/day versus ≤30 mg/day. Despite these discrepancies, most panelists agreed that it is the chronic exposure to GC that confers the major risk, and the statement received 96.3% agreement and mean (SD) LoA was 9.57 (0.77).

3. In patients not responding to hydroxychloroquine (alone or in combination with glucocorticoids) or patients unable to reduce glucocorticoids below doses acceptable for chronic use, addition of immunomodulating/immunosuppressive agents (eg, methotrexate (1b/B), azathioprine (2b/C) or mycophenolate (2a/B) and/or biological agents (eg, belimumab (1a/A) or anifrolumab (1a/A)) should be considered.
This statement emphasizes the value of conventional and biological immunomodulatory/immunosuppressive drugs for the control of the disease and facilitation of GC tapering and withdrawal. Since no new, high-quality data emerged in the past 4 years regarding conventional immunosuppressive drugs, deliberations regarding this statement focused on two main issues: (1) inclusion of anifrolumab, following its approval in 2021, as well as belimumab, as biological agents with proven efficacy in controlling disease activity, reducing flares, and allowing for GC dose reduction. The recommendation, there is no hierarchy in the choice between anifrolumab and belimumab, as the two drugs have not been compared in a head-to-head trial and their approval was the result of RCTs in similar extraarticular SLE populations. The panel noted that there are more than 10 years of real-life clinical experience with belimumab, while no real-life data for anifrolumab had been published by the time of the SLR completion. (2) The positioning of biological agents in relation to conventional immunosuppressive drugs for the treatment of SLE. For the latter point, while considerations from specific countries, healthcare settings and biological reimbursement policies have to be taken into account, most panels agreed that prior use of a conventional immunosuppressive drug (MTX, AZA, mycophenolate mofetil or mycophenolic acid (henceforth combined referred to as ‘mycophenolate’), see online supplemental table 1 for details), leflunomide or other drugs should not be mandatory for initiating anifrolumab or belimumab. Of note, this is unchanged from the 2019 recommendations. The rationale driving this statement was that, despite their substantially higher cost, approved biological drugs have proven their efficacy in high-quality RCTs, while such data are lacking for conventional immunosuppressive drugs, which continue to be used based on rheumatologists’ long-term real-life experience. This recommendation received 84.6% agreement and mean (SD) LoA was 9.32 (0.91).

4. In patients with organ-threatening or life-threatening disease, intravenous cyclophosphamide (2b/C) should be considered; in refractory cases, rituximab (2b/C) may be considered.

Due to its gonadal toxicity, high-dose IV CYC is reserved for severe cases of lupus, in which it may be considered owing to its high efficacy. Rituximab (RTX) is used off-label in SLE and is recommended in circumstances where other drugs have failed, with notable exceptions (eg, immune cytopenias, see below) where it can be used earlier. Although a universal definition of refractory disease is lacking in SLE, it is conceived as disease not responding to different classes of immunosuppressive medications. The combination of RTX with CYC had been used in early studies of RTX, but additional benefit has not been confirmed and this combination comes at the expense of an increased risk for infections. Sequential strategies of RTX followed by belimumab are being explored, but more data are needed.

Patients not responding to any of the aforementioned therapies might be offered other options, such as plasma exchange, haematopoietic stem cell transplantation or experimental therapies. In 2022, the use of CAR T-cells in five patients with severe, refractory SLE was published with encouraging results, yet RCTs and more long-term data are needed. Agreement for this recommendation was 100%, with mean (SD) LoA 9.38 (0.99).

5. Treatment of active skin disease should include topical agents (glucocorticoids, calcineurin inhibitors) (2b/B), antimalarials (hydroxychloroquine, chloroquine) (1a/A), and/or systemic glucocorticoids (4/C) as needed, with anifrolumab (1a/A), belimumab (1b/B), methotrexate (1b/B), or mycophenolate (4/C), considered as second-line therapy.

For the treatment of active skin disease in SLE, few new data have emerged since the 2019 recommendations, and a significant body of evidence continues to originate from studies in patients with cutaneous lupus erythematosus. Recommended first-line treatment (topical agents, antimalarials and/or systemic GC) has not changed in the statement. HCQ is the antimalarial of choice, but chloroquine may be used in the settings discussed earlier. Quinacrine (mepacrine) may also be used in cases of inadequate response or toxic retinopathy, as add-on to HCQ or alternative therapy, respectively, but its use is limited by frequent intolerance and unavailability in many countries.

For the ~40% of patients not responding to first-line therapy, comparative studies among existing immunosuppressive drugs are lacking. Despite this paucity, recommended second-line drugs have partly changed from 2019, because the Task Force decided to recommend drugs more familiar to rheumatologists (such as MTX or mycophenolate, instead of dapsone or retinoids). A small retrospective study in 73 patients with refractory CLE to first-line therapy found similar response rates (~65%) between MTX and mycophenolate. Anifrolumab and belimumab have both shown efficacy in mucocutaneous manifestations of SLE, although only anifrolumab has used the Cutaneous Lupus Area and Severity Index in its clinical programme, whereas belimumab has reported responses according to the general instruments SLEDAI and BILAG (hence, the designation B in the Grading of Recommendation, despite positive RCT data). Importantly, the list of recommended drugs is indicative and other treatments may be considered as second-line or third-line options, including dapsone, retinoids, CNI, AZA, CYC and RTX, ideally in collaboration with dermatologists experienced in the treatment of CLE. Finally, thalidomide and, more recently, lenalidomide, are effective in various subtypes of cutaneous lupus, and lenalidomide has a lower risk for polynuropathy than thalidomide; however, they should both be reserved for patients that have failed multiple previous agents, and with the utmost caution in women of reproductive age. This recommendation was agreed on by 96.3%, mean LoA (SD) was 9.35 (1.06).

6. In active neuropsychiatric disease attributed to SLE, glucocorticoids and immunosuppressive agents for inflammatory manifestations (1b/A) and antiplatelet agents/anticoagulants for atherothrombotic/antiphospholipid antibodies (aPL)-related manifestations (2b/C) should be considered.

This recommendation has remained unchanged, since no new data have emerged during the last 5 years that would deem a modification of the recommendation appropriate. Approach to a patient with possible neuropsychiatric SLE should follow the general principles as in the general population and symptomatic treatment as per individual manifestation should be considered. Attribution of a neuropsychiatric manifestation to SLE is challenging and published attribution models may be used in doubtful cases.

For severe inflammatory manifestations (eg, myelopathy, acute confusional state), potent immunosuppressive agents, like CYC or RTX, should be preferred. For the approved biological drugs anifrolumab and belimumab, there is a paucity of evidence regarding their efficacy in neuropsychiatric manifestations, because patients with active, severe forms of such manifestations were excluded from the RCTs of both drugs, and under-represented in real-life use of belimumab. Anticoagulant treatment is mainly indicated in cases of cerebrovascular disease, such as ischaemic stroke associated with aPL, because its value in other manifestations is not clear. Agreement on this recommendation was 96.3% and mean (SD) LoA was 9.68 (0.81).

7. For acute treatment of severe autoimmune thrombocytopenia, high-dose glucocorticoids (including pulses of intravenous
methylprednisolone) (4/C), with or without intravenous immuno- 
oglobulin G (4/C), and/or rituximab (2b/B), and/or high-dose 
intravenous cyclophosphamide (4/C), followed by maintenance 
therapy with rituximab (2b/B), azathioprine (2b/C), mycophene- 
olate (2b/C), or cyclosporine (4/C), should be considered. 

Similar to neuropsychiatric SLE, treatment of autoimmune 
thrombocytopenia in SLE also did not witness major develop- 
ments since 2019; thus, the current recommendation reflects the 
principles outlined in the previous update. A platelet number 
of 20–30,000/mm³ is typically used as the cut-off, below which 
therapy is indicated. Therapy includes: (1) acute phase treat- 
ment with GC (including pulses of intravenous MP; followed by 
0.5–0.7 mg/kg/day prednisone equivalent with tapering) with or 
without IVIG; RTX may also be used early in this setting,46 
based also on the drug’s documented efficacy in idiopathic immune 
thrombocytopenia, (2) early use of immunosuppressive medica-
tions as GC-sparing agents; a small retrospective study showed that 
patients with SLE with immune cytopenias who relapsed had 
less often received concomitant immunosuppressive agents 
following treatment of the initial episode.54 More importantly, 
mycophenolate was shown to reduce relapse when used as first 
line in a RCT in patients with immune thrombocytopenia.50 

While a similar RCT has not been performed in SLE, this study 
provided proof-of-concept for the first-line use of immunosup-
pressive medications in immune thrombocytopenia, a practice 
commonly followed by most rheumatologists. Regarding choice 
of drug for maintenance therapy, there is no hierarchy between 
the recommended drugs, and this is left to the treating physi-
cian’s discretion. In cases refractory to these drugs, thrombo-
poietin receptor (TPO) agonists and splenectomy are options; 
although the two modalities have not been formally compared 
in SLE and data mainly come from observational studies,60 it 
seems reasonable to use TPO agonists prior to splenectomy, 
given the possible complications and long-term sequelae of the 
 latter. However, it should be considered that TPO agonists have 
been associated with a higher risk of thromboembolic events, 
therefore their use should be avoided in aPL-positive patients.61 
Fostamatinib, a spleen tyrosine kinase inhibitor, is approved for 
the treatment of chronic immune thrombocytopenia, but has not 
been tested in SLE. Similar treatment options (excluding TPO 
agonists) pertain to SLE autoimmune haemolytic anaemia. This 
recommendation received 92.6% agreement and mean (SD) LoA 
was 9.48 (0.86).

8. Patients with active proliferative lupus nephritis should 
receive low-dose (EuroLupus) intravenous cyclophosphamide 
(1a/A) or mycophenolate (1a/A) and glucocorticoids (pulses of 
intravenous methylprednisolone followed by lower oral doses); 
combination therapy with belimumab (either with cyclophos-
phamide or mycophenolate (1b/A)) or calcineurin inhibitors 
-especially voclosporin or tacrolimus, combined with mycophe-
nolate, (1b/A) should be considered.

The recommendation regarding treatment of active LN 
received the highest attention, in light of the recent approvals of 
belimumab and voclosporin. Discussions revolved mainly 
around the position of these drugs in the therapeutic algorithm 
of LN, that is whether they should be used upfront in an early 
combination therapy with standard-of-care (SoC, low-dose 
CYC48 or mycophenolate in combination with GC, see online 
supplemental table 1 for usual drug doses in SLE), or whether 
they should be reserved for non-responding or relapsing disease. 
In this regard, deliberations towards the formulation of this 
recommendation focused on the following facts: (1) LN is by 
default severe disease, accompanied by increased morbidity 
and mortality, and leading to gradual nephron loss and chronic 
kidney disease (CKD),62 (2) rates of complete response at 1–2 
years with SoC therapy (ie, control arms) in recent clinical trials 
(including the phase 3 trials of belimumab and voclosporin, 
respectively)63,64 are consistently low, in the range of 20%–30%, 
and (3) both belimumab and voclosporin based on their RCTs 
have been approved for all patients with active LN, meaning that 
all patients can potentially receive them, including as first 
line. Of note, in a post-hoc analysis of the BLISS-LN, belimu-
mbum in combination with SoC was found to reduce the risk for 
flares by 55% compared with SoC alone, and preserve glomeru-
lar filtration rate (GFR) better than SoC.65 To this end, the 
possibility for a universal recommendation of early combination 
therapy aiming to increase renal response rates was intensively 
discussed among panellists. Counterarguments included the high 
cost of these therapies and the potential of overtreating some 
patients who would respond to treatment with mycopheno-
late or low-dose intravenous CYC alone, as well as respective 
cost or risk considerations, particularly relevant for long-term 
use of a CNI. Indeed, some patients with LN present with 
clinically and histologically milder disease, while others with risk 
markers for progression to end-stage kidney disease; at present, 
it is unclear which patients will benefit more from early combi-
nation therapies. Of note, recent real-life studies have reported 
higher response rates with SoC, compared with rates reported in 
RCTs.64 68 Based on all the above, it was proposed that early 
combination therapy ‘should be considered’ in all adult patients 
with active LN, emphasising the fact that treating physicians have 
the option to decide if and when combination therapy should 
be used. In the case of CNIs, combination refers to voclosporin 
as well as tacrolimus (TAC), since the current SLR confirmed 
the superiority of TAC+mycophenolate over SoC (mainly high-
dose CYC), although based on evidence exclusively from Asian 
populations.70

Additional points regarding the recommendation for LN 
warrant further clarification: first, no distinction between LN 
histological classes is made in the recommendation. It should 
be noted that neither belimumab nor voclosporin induced 
higher renal response rates versus placebo in a post-hoc RCT 
analysis of the small subgroup of patients with class V LN.66 71 
Nevertheless, patients with pure class V were underrepresented 
in these trials (less than 20%), and also there were fewer flares 
with belimumab in the pure V subgroup. Collectively, the Task 
Force opined that more data are needed to decide on the optimal 
treatment of class V LN; to provide a succinct message, it was 
elected that the statement considers patients with any class of 
LN that needs treatment. Of note, the recommended proteinuria 
cut-off for immunosuppressive treatment in class V LN remains 
1 g/day, as per the 2019 EULAR/ERA-EDTA recommendations.72 
Second, the secondary analysis of the BLISS-LN trial found 
that belimumab was more efficacious in patients with baseline 
proteinuria below 3 g/day.66 Third, voclosporin provided a rapid 
reduction in proteinuria, which may be preferable in patients 
with a high baseline urine protein in the nephrotic range.66 
Fourth, in AURORA-1, patients with baseline GFR<45 mL/min 
were excluded, thus the safety of voclosporin in patients with 
a low baseline GFR (30–45 mL/min) is as yet unclear. The final 
decision for the treatment of active LN should depend on the 
individual patient characteristics as outlined above (histological 
class, baseline GFR, proteinuria), presence of extrarenal mani-
festations, comorbidities, risk for toxicity, access to drugs and 
cost issues, and patient preferences. If a combination therapy is 
not opted for in patients with treatment-naïve LN, add-on treat-
ment with belimumab or voclosporin should be considered in 
patients with inadequate response by 3–6 months, or those who
flare. In these cases, physicians should consider to acquire expert consultation.

Regarding dosing of GC, pulses of intravenous MP (eg, 250–1000 mg for 1–3 days) are recommended as part of the initial (or ‘remission induction’) regimen, unless there are major safety concerns (eg, infection). For oral therapy, large controlled trials comparing different GC regimens have not been performed in LN. The 2019 EULAR/ERA-EDTA recommendations endorsed a lower dose GC regimen for initial therapy compared with traditional practices (starting dose 0.3–0.5 mg/kg/day and 20 mg/day for proliferative classes and class V, respectively), though acknowledging that this was not based on high-quality data. In the current version of recommendations, the principle for lower cumulative GC exposure was maintained. Importantly, belimumab demonstrated superior GC-sparing potential than SoC in the BLISS-LN study, while the AURORA study of voclosporin used significantly lower GC doses than earlier studies (20–25 mg/day starting oral prednisone rapidly tapered to 3 mg by 12 weeks), lending further support to their use in LN. A recommended GC initial dose and tapering strategy is shown in online supplemental table 1. The overall agreement for this recommendation was 92.8%, with a mean (SD) LoA of 9.36 (1.06).

Thrombotic microangiopathy (TMA) may be evident in up to 20% of LN biopsies, particularly in the presence of aPL, and is associated with an adverse impact on prognosis. Although not mentioned in the statement, treatment options in TMA-LN were discussed, even though high-quality data are lacking. In addition to anticoagulation therapy, there is emerging evidence for the use of eculizumab, a monoclonal antibody against complement protein C5 which is efficacious in cases of complement-mediated TMA, for patients with LN and histological evidence of TMA.

9. Following renal response, treatment of LN should continue for at least 3 years (2b/B); patients initially treated with mycophenolate alone or in combination with belimumab or a calcineurin inhibitor should remain on these drugs (1a/A), whereas mycophenolate or azathioprine should replace cyclophosphamide for those initially treated with cyclophosphamide alone (1a/A) or in combination with belimumab (1a/A).

Following the choice of initial treatment, renal response should be monitored according to the 2019 EULAR/ERA-EDTA targets (reduction in proteinuria ≥25% and 50% at 3 and 6 months, respectively, and below 500–700 mg/day at 12 months, all with GFR within 10% from baseline). These therapeutic goals have now been validated. Provided that response is achieved, subsequent (or ‘maintenance’) therapy should depend on the initial regimen. If the initial regimen included mycophenolate (either monotherapy or in combination with belimumab or voclosporin), then the same regimen should continue for at least 3 years; on the other hand, if low-dose CYC had been initially used, alone or in combination with belimumab, it should be replaced by mycophenolate or AZA while belimumab should be continued (if used initially).

Duration of immunosuppressive therapy was also intensively discussed. Immunosuppressive treatment in LN, particularly in proliferative classes, should continue for at least 3 years. Of note, in case of initial therapy with mycophenolate/CNI combination, there is a concern regarding the duration of therapy, as long-term use of ‘legacy’ CNI (tacrolimus, cyclosporine A) has been associated with nephrotoxicity and GFR decline. Several Asian RCTs have investigated CNI combination therapy as remission induction, but not as a long-term maintenance therapy.

In this regard, it is reassuring that the long-term AURORA-2 study extending to 3 years use of voclosporin/mycophenolate combination recently reported stable levels of GFR throughout the 3-year period. This recommendation was agreed on by 96.4% of participants and mean (SD) LoA was 9.56 (0.81).

10. In patients at high risk for kidney failure (defined as reduced glomerular filtration rate, histological presence of cellular crescents or fibrinoid necrosis, or severe interstitial inflammation), high-dose (National Institutes of Health regimen) intravenous cyclophosphamide (1a/A) in combination with pulse intravenous methylprednisolone can be considered. A subset of patients with LN present with baseline clinical and histological characteristics associated with an adverse long-term prognosis. Such patients can still be treated as in recommendation nr. 9, but it should be noted that patients with such characteristics are underrepresented or excluded in all recent trials in LN (eg, the BLISS-LN and AURORA-1 excluded patients with GFR <30 and ≤ 45 mL/min/1.73 m², respectively). Thus, the relative efficacy of these regimens in patients at high risk for kidney failure is currently unclear. A small (32 patients) post hoc analysis of the Aspreva Lupus Management Study found similar response rates (proteinuria and serum creatinine) between mycophenolate and high-dose intravenous CYC.

Thus, for patients presenting with impaired kidney function or histological evidence of crescentic glomerulonephritis and/or severe interstitial inflammation, the traditional high-dose intravenous CYC regimen (0.5–0.75 g/m² monthly for 6 months) can also be considered, since it is the most extensively studied therapeutic regimen in severe LN, in the early studies from the NIH. Importantly, this recommendation received 100% agreement among Task Force members, and a mean (SD) LoA of 9.57 (0.86).

Figures 1 and 2 outline the existing treatment options for the management of extrarenal SLE and LN, respectively.

11. In patients with SLE achieving sustained remission, gradual tapering of treatment should be considered, with withdrawal of glucocorticoids first (2a/B).

The possibility of tapering immunosuppressive treatment in patients with SLE with quiescent disease was a specific research question for the SLR, and concerned GC, immunosuppressive drugs (conventional and biological), and finally, HCQ (in this sequence). Regarding GC, a meta-analysis calculated a 24% pooled incidence of SLE flares following GC discontinuation, but relative risk for major flares was not increased compared with patients who continued GC. In an investigator-initiated study from France, discontinuation of prednisone in patients who had clinically quiescent disease for more than 1 year and received stable 5 mg/day proved inferior to continuation of the same dose, in terms of risk of disease flares. Caveats of this study were discussed between Task Force members, mainly the abrupt discontinuation of prednisone and the fact that biological agents like belimumab were not received by any patient. It was decided that these limitations, together with observational studies that have shown no increased risk of flares with gradual tapering of GC to complete withdrawal and the detrimental effects of long-term GC use, allow for a recommendation that gradual GC tapering to discontinuation should be attempted in SLE, in line with current recommendation 2.

Regarding immunosuppressive agents, a second investigator-initiated RCT (Weaning of Immunosuppression in Lupus, WIN-LUPUS) tested whether withdrawal of mycophenolate or AZA after 2–3 years of therapy in LN would be non-inferior to continuation for the occurrence of renal relapses. The study failed to show non-inferiority, as patients in the discontinuation group had more relapses of LN and more extrarenal flares. On the contrary, similar to GC, uncontrolled observational studies have reported successful withdrawal of immunosuppressive therapy...
## Recommendation

### Treatment of Non-Renal Systemic Lupus Erythematosus

<table>
<thead>
<tr>
<th>General measures</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun protection</td>
<td>Remission Clinical SLEDAI≤0</td>
</tr>
<tr>
<td>Exercise</td>
<td>HCQ GC ≤ 5 mg/dy</td>
</tr>
<tr>
<td>No smoking</td>
<td>or</td>
</tr>
<tr>
<td>Balanced diet</td>
<td>Low disease activity SLEDAI ≤4</td>
</tr>
<tr>
<td>Vaccinations</td>
<td>HCQ GC ≤ 5 mg/dy</td>
</tr>
<tr>
<td>Normal body weight</td>
<td>Immunosuppressive or biological agents at stable, tolerated dose</td>
</tr>
<tr>
<td>Blood pressure, lipid, glucose control</td>
<td></td>
</tr>
<tr>
<td>Acetylsalicylic acid, VKA</td>
<td></td>
</tr>
<tr>
<td>(in aPL+/APS)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Assess adherence to treatment</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Figure 1

Treatment of non-renal systemic lupus erythematosus. Top-to-bottom sequence does not imply order of preference (eg, MTX, AZA and MMF are equal options for second-line therapy in mild disease or first-line therapy in moderate disease). *Mild disease: constitutional symptoms; mild arthritis; rash ≤9% body surface area; platelet count (PLTs) 50–100 x 10^9/L; SLEDAI≤6; BILAG C or ≤1 BILAG B manifestation. *Moderate disease: moderate–severe arthritis ('RA-like'; rash 9%–18% BSA; PLTs 20–50 x 10^9/L; serositis; SLEDAI 7–12; ≥2 BILAG B manifestations). *Severe disease: major organ threatening disease (cerebritis, myelitis, pneumonitis, mesenteric vasculitis); thrombocytopenia with platelets<20 x 10^9/L; TTP-like disease or acute haemophagocytic syndrome; rash>18% BSA SLEDAI>12; ≥1 BILAG A manifestations. *Recommendation of belimumab and anifrolumab as first-line therapy in severe disease refers to cases of extrarenal SLE with non-major organ involvement, but extensive disease from skin, joints, and so on. The use of anifrolumab as add-on therapy in severe disease refers mainly to severe skin disease. For patients with severe neure_psychiatric disease, anifrolumab and belimumab are not recommended. ANI, anifrolumab; aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; AZA, azathioprine; BEL, belimumab; BILAG, British Isles Lupus Assessment Group; CNI, calcineurin inhibitor; CYC, cyclophosphamide; GC, glucocorticoids; HCQ, hydroxychloroquine; IV, intravenous; MMF, mycophenolate mofetil; MTX, methotrexate; PO, per os; RTX, rituximab; SLEDAI, SLE Disease Activity Index; VKA, vitamin K antagonists.

In LN. Of note, the total duration of therapy as well as of remission prior to discontinuation of immunosuppressive drugs are particularly important in the LN setting; patients should have received at least 3–5 years of therapy and be in remission for at least 2 years before withdrawal can be attempted. Prior to withdrawal, tapering should be undertaken very gradually. A repeat kidney biopsy-guided decision for therapy withdrawal in patients in clinical remission, in order to assess for residual histological activity predictive of a subsequent flare, is supported by recent observational studies and could be considered, although this has not been formally tested in a RCT.

Contrary to GC and immunosuppressive drugs, HCQ should not be discontinued in patients with SLE in the absence of unacceptable side-effects; in addition to its multiple benefits including survival, the SLR concluded that HCQ discontinuation is associated with increased risk for flares (data from observational studies). Additionally, HCQ therapy is a protective factor against disease relapse in patients discontinuing GC or immunosuppressive agents. Although complete discontinuation is discouraged (with the exception of adverse effects), data on tapering/dose reduction are equivocal; thus, a decision for HCQ dose reduction in patients in remission should be taken on an individualised basis.

Importantly, the statement on tapering treatment in quiescent SLE received the highest LoA between members, 100%, and mean (SD) LoA 9.89 (0.38).

12. SLE associated with thrombotic antiphospholipid syndrome (APS) should be managed with long-term vitamin K antagonists after the first arterial or unprovoked venous thrombotic event (1b/B); low-dose aspirin (75–100 mg/day) should be considered in patients with SLE/without APS with high-risk aPL profile (2a/B).

Patients with SLE with concomitant APS represent a challenging endotype of the lupus spectrum. To this end, although EULAR has published specific recommendations for the management of APS in 2019, it was decided that the significance of SLE-APS merits a specific question for the SLR. Management of definite SLE-aPL/APS should follow the same principles of therapy as primary APS, including the long-term use of vitamin K antagonists with high-risk aPL profile (2a/B).
Congratulations! You have completed the natural text extraction for the given document. Here is the extracted text in a plain text format:

**Recommendation**

**Treatment of Lupus Nephritis**

<table>
<thead>
<tr>
<th>Adjunct treatment for kidney protection*</th>
<th>Subsequent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Targets</td>
</tr>
<tr>
<td>HCQ (all patients unless contraindicated)</td>
<td>3 months</td>
</tr>
<tr>
<td>GC PO/IV (consider pulse IV MP, then 0.3-0.5 mg/kg/day depending on severity; taper to ≤ 5 mg/day as quickly as possible)</td>
<td>≥25% reduction in UPr</td>
</tr>
<tr>
<td>MMF</td>
<td>6 months</td>
</tr>
<tr>
<td>MMF/low-dose CYC + BEL§</td>
<td>≥50% reduction in UPr to &lt;3 gr/day</td>
</tr>
<tr>
<td>MMF/aza/MF + BEL§</td>
<td>12 to 24 months</td>
</tr>
<tr>
<td>MMF + CNI (esp. VOC, TAC)</td>
<td>UPr &lt;0.5-0.7 gr/day</td>
</tr>
<tr>
<td>High-dose CYC §,¶</td>
<td>(all with eGFR within 10% from baseline)</td>
</tr>
</tbody>
</table>

Figure 2  Treatment of lupus nephritis. Top-to-bottom sequence does not imply order of preference (similar to figure 1). *In addition to general protective measures, as outlined in figure 1. §BEL should always be given in combination with MMF or low-dose CYC as initial therapy, and with MMF or AZA as maintenance therapy. ¶CNIs should be given in combination with MMF. *Particularly recommended in the presence of poor prognostic factors; reduced eGFR, histological presence of cellular crescents or fibrinoid necrosis, or severe interstitial inflammation. ¶Extension of high-dose CYC to subsequent phase refers to severe LN cases, in which bimonthly or quarterly CYC pulses may be given following six monthly pulses. In relapsing/refractory disease, especially after failure to CYC-based regimens. ACEi, angiotensin-converting enzyme inhibitors; APS, antiphospholipid syndrome; ARB, angiotensin receptor blockers; AZA, azathioprine; BEL, belimumab; CNI, calcineurin inhibitor; CYC, cyclophosphamide; eGFR, estimated glomerular filtration rate; GC, glucocorticoids; HCQ, hydroxychloroquine; IV, intravenous; MMF, mycophenolate mofetil; eGFR, estimated glomerular filtration rate; GC, glucocorticoids; HCQ, hydroxychloroquine; IV, intravenous; MMF, mycophenolate mofetil; PO, per os; RTX, rituximab; SGLT2i, sodium glucose transporter 2 inhibitors; TAC, tacrolimus; Upr, urine protein; VKA, vitamin K antagonists; VOC, voclosporin.

vitamin K antagonists versus DOACs in patients with thrombotic APS. A recent meta-analysis of these trials showed that DOAC use was associated with increased risk of subsequent arterial thrombotic events (OR: 5.43), especially stroke (OR: 10.74), and the composite of arterial or venous thrombotic events (OR: 4.46). In patients who have not experienced a thrombotic event, primary prophylaxis with low-dose aspirin should be considered in those with a high risk aPL profile, defined as lupus anticoagulant positivity, or double (any combination of lupus anticoagulant, anticardiolipin antibodies or anti-beta2glycoprotein I antibodies) or triple aPL. Apart from its other beneficial effects, HCQ has also potential antithrombotic effects and may reduce aPL levels, and is particularly recommended in patients with SLE-aPL or SLE/APS.

Catastrophic APS (CAPS) is a rare complication of APS, with concomitant or successive thrombosis in ≥3 organs. Although a detailed overview of the therapeutic options for CAPS was outside the scope of the SLR, several Task Force members deemed it important to cover this issue in the manuscript text. High-quality studies for the treatment of CAPS in SLE are lacking. Precipitating conditions (eg, infections) should be aggressively sought for and treated, to minimise the risk for the development of CAPS. Triple therapy with full anticoagulation, high-dose GC and plasma exchange and/or IVIG is recommended for patients with CAPS; more recently, the complement inhibitor eculizumab has shown promise, especially in patients with CAPS with features of complement-mediated TMA (microangiopathic haemolytic anaemia, thrombocytopenia, acute kidney injury). The 2019 EULAR recommendations for the management of APS stated that complement inhibitors or RTX may be considered in refractory CAPS. Agreement for this recommendation was 96.4% and mean (SD) LoA was 9.57 (0.83).


The final recommendation is a statement regarding major comorbidities in SLE, reflecting expert opinion based on the evidence for the general benefit of the mentioned measures. As on APS, EULAR has issued specific recommendations regarding vaccinations in patients with autoimmune rheumatic diseases, including SLE, and the reader is referred to the respective manuscripts for further details. In view of the COVID-19 pandemic and the burden of herpes zoster in patients with lupus, the current SLR included a research question regarding the efficacy and safety of vaccines against SARS-CoV-2 and herpes zoster virus.
Box 1 Future research agenda in systemic lupus erythematosus (SLE)

Existing therapies
⇒ Utility of measurement of drug blood levels (hydroxychloroquine, mycophenolate, etc)
⇒ Randomised trials testing different initial glucocorticoid doses and different tapering regimens
⇒ Optimal duration of therapy and timing of immunosuppression discontinuation (both for renal and extrarenal disease)
⇒ Value of repeat kidney biopsy prior to immunosuppression discontinuation
⇒ Value of per-protocol repeat kidney biopsy after one year of treatment to guide further treatment
⇒ Prediction of flare in patients who taper drugs
⇒ Prediction of flare in patients who attain the treatment target
⇒ Use of statins, low-dose aspirin and other conventional therapies to prevent cardiovascular disease

Pathophysiology and biomarkers
⇒ Pre-SLE cohort initiatives to delineate who is at risk to develop SLE and what are the sequential ‘hits’ that lead to disease development
⇒ Involvement of particular organ systems over others, multisystem versus organ-dominant disease
⇒ Prediction of response to specific therapies (by clinical, cellular and/or molecular markers)
⇒ Biomarkers for response to different biological drugs (pharmacogenetics, transcriptomics, etc)

Clinical trial design and new drug development
⇒ Optimisation of clinical trial design and study endpoints to maximise probability of new drug approval
⇒ Handling of background medication to avoid polypharmacy and ‘dilution’ of positive effects of drugs under study
⇒ Inclusion of organ-specific endpoints and better and more sensitive measurements of disease activity
⇒ Increase in number of adequately trained trial sites (recruitment, infrastructure and training)
⇒ Academia versus industry-driven clinical trials
⇒ Evaluation and standardisation of patient-reported measures of disease activity/outcomes

Clinical trial design and new drug development
⇒ Optimisation of clinical trial design and study endpoints to maximise probability of new drug approval
⇒ Handling of background medication to avoid polypharmacy and ‘dilution’ of positive effects of drugs under study
⇒ Inclusion of organ-specific endpoints and better and more sensitive measurements of disease activity
⇒ Increase in number of adequately trained trial sites (recruitment, infrastructure and training)
⇒ Academia versus industry-driven clinical trials
⇒ Evaluation and standardisation of patient-reported measures of disease activity/outcomes

(HZV) in lupus. Both the live attenuated and the more efficacious recombinant zoster vaccine have been used in patients with SLE and, although studies are limited, they are considered safe.104 105 Similarly, several observational studies have proven the immunogenicity and safety of SARS-CoV-2 vaccines, which are recommended for patients with SLE.106 Prompt identification and management of infections/sepsis are essential in SLE, and vigilant monitoring for opportunistic infections is warranted in selected patients receiving potent immunosuppressive drugs (eg, high-dose GC, CYC, RTX).107 In patients with LN, adjunct treatment with nephroprotective agents is of utmost importance to decelerate nephron loss, in combination with immunosuppressive therapy. Renin–angiotensin–aldosterone blockade is required, unless not tolerated, to control hypertension (target level below 130/80 mm Hg).108 More recently, novel classes of agents, mainly sodium glucose transport 2 (SGLT-2) inhibitors (‘flozins’), have gained attention as kidney protective drugs for any case of CKD; SGLT-2 is expressed in kidney biopsies of patients with LN,109 and its targeting seems reasonable. A preliminary study of dapagliflozin in a small number of patients with SLE (18 with LN) found no difference in proteinuria following therapy.110 Until more data are available, SGLT-2 inhibitors may be considered in patients with LN with reduced GFR below 60–90 mL/min or proteinuria more than 0.5–1 g/day, on top of ACE/ARB/ during the maintenance phase. The final recommendation received 92.8% agreement and mean (SD) LoA was 9.83 (0.36).

DISCUSSION
For these recommendations, we assembled a Task Force of world-leading experts in the field of SLE from four continents, to assure the widest possible representation and broad expertise. This is particularly important, because SLE across the world is very different in terms of presentation and severity. To this end, the current set of recommendations sought to ensure a fair balance, and guarantee equal representation of mild, moderate and severe disease, the relative frequency of which may well vary between different countries and continents.

A major modification to the previous sets of EULAR recommendations for SLE was the reduction of the number of individual recommendations. Indeed, to align with the EULAR SOPs but also streamline and simplify the recommendations and facilitate their dissemination, the Task Force managed to condense the recommendations to 13 (with 5 overarching principles). Similar to the 2019 version, the first recommendations (1–4) refer to optimal use of commonly used drugs, recommendations 5–12 deal with specific organ manifestations, and the final recommendation covers the issue of adjunct treatments and comorbidities.

Regarding the use of individual drugs, the emphasis on a more restricted use of GC evolved further from the 2019 recommendations. Thus, GC should be used only if needed, as for mild forms of SLE HCQ alone may suffice. A maximum recommended maintenance dose of 5 mg/day prednisone equivalent is now recommended, stricter than the 7.5 mg/day in the previous recommendations. Of note, this change did not come in view of new high-quality data or RCTs, although we found observational studies linking mean prednisone doses 5 mg/day with adverse sequelae. Nevertheless, there was unanimous agreement among Task Force members that a strong recommendation for a lower dose of GC should be given in view of the detrimental effects of their long-term use and the approval of new agents with GC-sparing effects.

To avoid long-term exposure to GC, early use of immunosuppressive drugs is recommended in SLE. The sequence between conventional and biological drugs was a matter of extensive debate within the Task Force. Nevertheless, in 2019, it was already stated that add-on treatment with belimumab (then the only approved biologic) ‘should be considered in patients not responding to combinations of HCQ and GC with or without immunosuppressive agents’. Thus, it was agreed that placing biological drugs (now, belimumab and anifrolumab) after failure of conventional drugs would constitute a step backwards from 2019. To this end, the current recommendations do not require prior failure to one or more conventional drugs before initiating a biological agent, although for the majority cases it may be prudent to try at least one conventional immunosuppressive.

Since 2019, anifrolumab was approved for the treatment of extrarenal SLE in 2021. On the other hand, there is now more than 10 years real-life experience with belimumab, with results confirming good control of disease activity, reduction of flares and halting of damage accrual.111 112 The two drugs


Ann Rheum Dis: first published as 10.1136/ard-2023-224762 on 12 October 2023. Downloaded from http://ard.bmj.com/ on December 22, 2023 by guest. Protected by copyright.
have a different mechanism of action and have not been directly compared. Two indirect treatment comparison studies (each supported by each one of the manufacturing companies and using a different patient database) reported conflicting results at low levels of evidence and high risk of bias and, therefore, cannot be interpreted as comparative efficacy studies. Thus, with current evidence, the two drugs are recommended with no hierarchy between them. Of note, both drugs seem to have better efficacy in serologically active patients at baseline, although this should not limit their use to this subset of patients.

Undoubtedly, the most expected outcome of the current update was the verdict regarding the positioning of belimumab and voclosporin in the treatment of LN. The rationale behind the phrasing that early combination therapy with either belimumab or a CNI ‘should be considered’ reflects the fact that worldwide treatment recommendations for SLE should take into account different patient characteristics, but also variable access to drugs in high-income versus low-income countries. If an early combination therapy is chosen, specific patient characteristics may favour belimumab over a CNI or vice versa, for instance, the presence of extrarenal disease activity for belimumab, or nephrotic-range proteinuria for CNI. Importantly, an update of dedicated EULAR recommendations for the management of LN is currently being scheduled.

Patients with SLE experience a wide variety of symptoms, which extend beyond the classical manifestations that require immunosuppressive therapy. Indeed, symptoms such as fatigue, non-inflammatory pain, mood disturbance and cognitive dysfunction are among the ones most frequently referred and valued by patients. A recently proposed system categorised symptoms of SLE in two types: the typical inflammatory symptoms (‘type 1’) requiring immunosuppression, and symptoms such as those mentioned above (‘type 2’), which do not respond to immunosuppressive therapy, yet often dominate patient-reported outcomes. We acknowledge that the current recommendations mainly address classic inflammatory SLE manifestations, in part because the Task Force felt that the data on type 2 symptoms are not so robust to justify specific management recommendations. Nevertheless, a holistic care of patients with SLE should value and address all symptoms mentioned by patients, both those requiring immunosuppressive therapy, as well as those in need of complimentary approaches.

A crucial point pertaining to any set of management recommendations is their implementation in real-life clinical practice, often not self-explanatory because recommendations by definition cannot capture all aspects of everyday clinical practice. To tackle this need, the EULAR SOPs suggest the definition of quality indicators in tabular form, at least for the most relevant recommendations, to serve as a checklist for treating physicians and facilitate rate of adherence after a reasonable period of time. Importantly, following the issue of the 2019 EULAR recommendations, to serve as a checklist for treating physicians around the world. Further issues for the future research agenda in SLE are shown in box 1. This updated version will inform rheumatologists and nephrologists, health professionals, patients, regulators, payers and other stakeholders on the way modern treatment of SLE is perceived from experts in the field spanning four continents. It is the hope of this Task Force that the developments in the treatment of SLE will continue at such pace to mandate a new update of the EULAR recommendations within the next 3 years.

Author affiliations
1Rheumatology and Clinical Immunology Unit, “Aktikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
2Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany
3Division of Rheumatology, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S 1109, Centre National de Référence des Maladies Auto-immunes Systémiques Rares (RESO), Strasbourg, France
4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang Institute of Bioscience and Biotechnology, Seoul, South Korea
5Department of Nephrology and Renal Transplantation Unit, “Laiko” General Hospital, Medical School, National and Kapodistrian University of Athens, Greece
6Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK; National Institute for Health Research Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
7Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK
8Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy
9Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin; Deutsches Rheumaforshungszentrum, Berlin, Germany
10Department of Rheumatology, University of Cambridge, Cambridge, UK
11Lupus Programme, Centre for Prognosis Studies in the Rheumatic Disease, Schroeder Arthritis Institute, Kembrell Research Institute, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
12Service de Rhumatologie, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
13Department of Rheumatology, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal; School of Health Sciences, Universidade da Beira Interior, Covilha, Portugal
14Department of Medicine, University of Cambridge, Cambridge, UK
15Cyprus League Against Rheumatism, Aglantzia, Cyprus
16Department of Rheumatology and Immunology, Faculty of Medicine, University of Szeged, Hungary
17Department of Medicine, Tuen Mun Hospital, Hong Kong, China
18Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
19Division of Biomedical Sciences Humanities University, Nephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Milan, Italy
20Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
21Department of Rheumatology & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany
22Division of Rheumatology, University of Padova, Padova, Italy
23Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
24Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
25Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
26Rheumatology Department, Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) - VIGO Group, Galicia Sur Health Research Institute, Vigo, Spain
27Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
28Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
29First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Acknowledgements

The committee wishes to acknowledge the support of the EULAR Standing Committee on Clinical Affairs. The committee also expresses its sincere appreciation and gratitude to the EULAR Secretariat, especially Simona Lupattelli, executive assistant, and to Dora Toga for the outstanding organisation and coordination.

Contributors

AF and MK reviewed the literature and AF drafted the manuscript. GB and CBM supervised the methodology. All authors edited the manuscript. DTB supervised the project.

Funding

European League against Rheumatism (project number QoC015).

Competing interests

AF reports honoraria and/or consulting fees from Lilly, Biogen, Novartis, AbbVie, Astra Zeneca, GSK, MSD, Pfizer, UCB, Amgen, Aepnosia, support for attending meetings from UCB. MK reports honoraria and/or consulting fees from GSK, participation in advisory boards from GSK, Astra Zeneca, Amgen. JA reports honoraria and/or consulting fees from Novartis, Astra Zeneca, support for attending meetings from Novartis, Astra Zeneca, participation in advisory boards from Roche, Astra Zeneca (all paid to Lupus Europe). MA reports honoraria and/or consulting fees from AbbVie, Astra Zeneca, GSK, Otsuka, Roche, support for attending meetings from Pfizer. LA reports grants from GSK, honoraria and/or consulting fees from Alexion, Alpine, Amgen, Astra Zeneca, AbbVie, Biogen, BMS, Boehringer-Ingelheim, Chugai, GSK, Grifols, Idorsia, Janssen, Kezar, Lilly, Medac, Novartis, Ono pharmaceuticals, Pfizer, Roche, UC B, support for attending meetings from Novartis, Astra Zeneca. INB reports grants from GSK, Janssen, honoraria and/or consulting fees from Astra Zeneca, GSK, Eli Lilly, UCB, MSD, participation in advisory boards from Novartis, Astra Zeneca, ITOO. RC reports honoraria, consulting fees and/or participation in advisory boards from AstraZeneca, Celgene, GSK, Janssen, Lilly, Pfizer, UCB, Rubió, Werfen. AD reports honoraria and consulting fees from Otsuka, Astra Zeneca, GSK, Lilly. TD reports consulting fees from Roche, Novartis, GSK, Astra Zeneca, participation in advisory boards from GNE, Roche, Novartis.

DDG reports grants from AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, UCB, consulting fees from AbbVie, Amgen, Astra Zeneca, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, UCB. FAH reports grants from GSK, Roche. DI reports grants from GSK, Roche, CSL Vifor, honoraria and consulting fees from Astra Zeneca, Chemocentryx, GSK, Novartis, Takeda, CSL Vifor, participation in advisory boards from Chinpoc, GSK, stocks in Auviria. UK reports honoraria from honoraria from Janssen, Takeda, support for attending meetings from AbbVie, Astra Zeneca, CSL Behring, participation in advisory boards from Sxivo Pharma, Roche, Astra Zeneca. CCM reports honoraria and/or consulting fees from GSK, support for attending meetings from Novartis. EFM reports grants from AbbVie, AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly and Company, EMDSeronet, Genentech, GlaxoSmithKline, Janssen, and UCB, honoraria and/or consulting fees from AbbVie, Astra Zeneca, Biogen, Bristol Myers Squibb, Eli Lilly and Company, EMDSeronet, Galapagos, Genentech, Gilead, GlaxoSmithKline, IGM, Janssen, Novartis, Servier, Wolf, Zenas, support for attending meetings from AstraZeneca, Roche. GM reports honoraria from GSK, Roche, Otsuka, participation in advisory boards from GSK, Otsuka. MM reports honoraria and/or consulting fees from AstraZeneca, Eli Lilly, GSK, UCB, support for attending meetings from Pfizer, support for attending meetings from AstraZeneca, Roche, participation in advisory boards from Roche, Astra Zeneca, participation in advisory boards from GSK, Otsuka, Gebro, Astra Zeneca, Boehringer-Ingelheim, MSD. BAPE reports grants from Janssen, support for attending meetings from Astra Zeneca, participation in advisory boards from GSK, Otsuka, Roche, Astra Zeneca, participation in advisory boards from GSK, Otsuka, Gebro, Astra Zeneca, Boehringer-Ingelheim, MSD. BAPE reports grants from Janssen, support for attending meetings from Astra Zeneca, participation in advisory boards from Astra Zeneca, E3 reports grants from AstraZeneca, GSK, Janssen, support for attending meetings from Astra Zeneca, participation in advisory boards from Astra Zeneca, Otsuka, Janssen, Novartis, Pfizer, UCB, support for attending meetings from Astra Zeneca, GSK, Novartis, Otsuka, Roche, participation in advisory boards from Astra Zeneca, GSK, Novartis, medical writing from Astra Zeneca, GSK. JMP reports grants from GSK, Pfizer, honoraria fees from GSK, Astra Zeneca, Lilly, support for attending meetings from GSK, Astra Zeneca, participation in advisory boards from GSK, Otsuka, Gebro, Astra Zeneca, Boehringer-Ingelheim, MSD. BAPE reports grants from Janssen, support for attending meetings from Astra Zeneca, participation in advisory boards from GSK, Otsuka, Gebro, Astra Zeneca, Boehringer-Ingelheim, MSD. BAPE reports grants from Janssen, support for attending meetings from Astra Zeneca, participation in advisory boards from Astra Zeneca, GSK, Otsuka, UCB, participation in advisory boards from Janssen, Otsuka, support for attending meetings from AbbVie, AstraZeneca, Lilly, Galapagos, royalties or licenses from Elsevier, honoraria and/or consulting fees from AbbVie, Galapagos/Gilead, Novartis, BMS, Samsung, Sanofi, Chugai, R-Pharma, Lilly, MSD, Janssen, participation in advisory boards from Astra Zeneca. E3 reports grants from Astra Zeneca, GSK, Janssen, support for attending meetings from Astra Zeneca, participation in advisory boards from Astra Zeneca.

Provenance and peer review

Not commissioned; externally peer reviewed.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been formally peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation or adaptation or otherwise.

ORCID iDs

Antonis Fanouriakis http://orcid.org/0000-0003-2696-031X
Myro Kostopoulos http://orcid.org/0000-0002-8832-7475
Martin Aringer http://orcid.org/0000-0003-4471-8375
Laurent Arnaud http://orcid.org/0000-0002-8077-8394
Sang-Chol Bae http://orcid.org/0000-0003-4658-1093
Andrea Doria http://orcid.org/0000-0003-0548-4983
Thomas Dörner http://orcid.org/0000-0002-6478-7725
Richard A Furie http://orcid.org/0000-0001-6712-1585
Dafna D Gladman http://orcid.org/0000-0002-9074-0592
Frederic A Housseau http://orcid.org/0000-0003-1451-083X
Louis Sousa Inês http://orcid.org/0000-0003-3192-8570
David Jayne http://orcid.org/0000-0002-1712-0637
Chi Chiu Mok http://orcid.org/0000-0003-3696-1228
Eric F Moran http://orcid.org/0000-0002-9507-3338
Johanna Mucke http://orcid.org/0000-0001-8915-7837
Chetan B Mukhtar http://orcid.org/0000-0002-9771-6667
Jin Young Nagy http://orcid.org/0000-0003-198-3228
Ioannis Paradis http://orcid.org/0000-0002-4875-5395
Michelle Petri http://orcid.org/0000-0003-1441-5373
Elisabet Svenungsson http://orcid.org/0000-0003-3396-3244
Yoshiha Tanaka http://orcid.org/0000-0002-0807-7139
Maria G Tektonidou http://orcid.org/0000-0003-2238-0975
SK Onno Teng http://orcid.org/0000-0001-9920-2195
Angela Tincani http://orcid.org/0000-0003-4355-9232
Edward M Vital http://orcid.org/0000-0003-1637-4755
Ronald F van Vollenhoven http://orcid.org/0000-0001-6438-8663
Chris Wincup http://orcid.org/0000-0002-8742-8311
George Bertias http://orcid.org/0000-0001-5299-1406
Dimitrios T Boumpas http://orcid.org/0000-0002-9812-4671

REFERENCES


2 Bertias GS, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations:


Comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis: a randomized trial.


Two-arm randomised controlled trial for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.


A secondary analysis of the belimumab phase 3 trial.


Aurora 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.


Long-term follow-up of an inception cohort.

Weaning of immunosuppressive therapy in lupus nephritis: a 100-case report.


Arthritis Care Res (Hoboken) 2022;73:1399–408.


Arthritis Care Res (Hoboken) 2022;81:1087–90.


Arthritis Care Res (Hoboken) 2022;73:1399–408.
Recommendation


